Jump to content

Talk:Dacomitinib

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Improved PFS in NSCLC - ASCO 2017

[edit]

Could mention Dacomitinib Sets PFS Record in Phase III NSCLC Trial. 2017 : "...Dacomitinib treatment extended median progression-free survival by 5.5 months versus gefitinib -- to 14.7 months -..." & toxicity issues - Rod57 (talk) 10:05, 9 June 2017 (UTC)[reply]

Clarify inhibitory effect on normal and various mutated forms of EGFR

[edit]

The trials seem to be on patients with mutated EGFR but does it also inhibit normal EGFR ? - Rod57 (talk) 10:17, 9 June 2017 (UTC)[reply]